liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Pharmacogenomics of importance for paclitaxel chemotherapy
Linköping University, Faculty of Health Sciences. Linköping University, Department of Medicine and Health Sciences, Clinical Pharmacology .
2008 (English)In: Pharmacogenomics (London), ISSN 1462-2416, E-ISSN 1744-8042, Vol. 9, no 6, 671-674 p.Article in journal (Refereed) Published
Abstract [en]

Paclitaxel (Taxol®) has a broad activity spectrum and is clinically used, often in combination with carboplatin, to treat breast, ovarian and lung cancer. The response to treatment and the severity of adverse drug reactions after chemotherapy varies greatly among individuals, and one of the most important factors responsible for these differences is now recognized to be the genetic variability. However, so far only genetic variants of ABCB1 have been indicated to be associated with response and pharmacokinetics of paclitaxel. Commercially, the patent on paclitaxel has expired: however, from a healthcare perspective, it would be beneficial to identify patients with risk of poor response or high risk of toxicity to reduce hospitalization costs. This artiicle focuses on the pharmacogenomic background for paclitaxel response and interindividual variability.

Place, publisher, year, edition, pages
2008. Vol. 9, no 6, 671-674 p.
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:liu:diva-44478DOI: 10.2217/14622416.9.6.671Local ID: 76790OAI: oai:DiVA.org:liu-44478DiVA: diva2:265340
Note
Original Publication: Henrik Green, Pharmacogenomics of importance for paclitaxel chemotherapy, 2008, Pharmacogenomics, (9), 6, 671-674. http://dx.doi.org/10.2217/14622416.9.6.671 Copyright: Future Medicine http://www.futuremedicine.com/ Available from: 2009-10-10 Created: 2009-10-10 Last updated: 2017-12-13

Open Access in DiVA

fulltext(190 kB)894 downloads
File information
File name FULLTEXT01.pdfFile size 190 kBChecksum SHA-512
1c84bb02109e73360e96b2d152d42137e45c2397be05202f568cf682b490da1413aea3b31f9011b37f305e3fd6a3d61d4b7ed0e9fb2058191c452dcd1bd57cc6
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Authority records BETA

Green, Henrik

Search in DiVA

By author/editor
Green, Henrik
By organisation
Faculty of Health SciencesClinical Pharmacology
In the same journal
Pharmacogenomics (London)
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 894 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 150 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf